Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...